Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Chemomab TherapeuticsCMMB +5.11%36 Equity-to-Asset is 0.91 as of Mar. 2026, which is 5% above its 10-year median of 0.87. GuruFocus rates CMMB with a GF Score™ of 36/100. Among 1,416 Biotechnology companies, Chemomab Therapeutics ranks better than 85.95% on this metric.
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Chemomab Therapeutics Equity-to-Asset Related Terms
Chemomab Therapeutics Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for Chemomab Therapeutics's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CMMB vs TOVX, BIVI, CRIS: Equity-to-Asset Comparison
For the Biotechnology subindustry, Chemomab Therapeutics's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Chemomab Therapeutics Equity-to-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Chemomab Therapeutics's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Chemomab Therapeutics's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Chemomab Therapeutics's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Chemomab Therapeutics (CMMB) has a Equity-to-Asset of 0.91 as of Mar. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Chemomab Therapeutics and its competitors. This is near median its historical median of 0.87. Over the past decade, Chemomab Therapeutics' Equity-to-Asset has ranged from 0.69 to 0.97. According to the industry distribution chart, Chemomab Therapeutics ranks #199 out of 1416 companies in the Biotechnology industry, placing it in the top 14.1%.
Is Chemomab Therapeutics' Equity-to-Asset too high?
Chemomab Therapeutics' current Equity-to-Asset of 0.91 is near median its 10-year median of 0.87. Over the past 10 years, this metric has ranged from a low of 0.69 to a high of 0.97. The Biotechnology industry median Equity-to-Asset is 0.68. Chemomab Therapeutics' value of 0.91 is 33.8% above this industry median. Based on the distribution chart, Chemomab Therapeutics ranks #199 out of 1416 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Chemomab Therapeutics has a GF Score™ of 36/100, reflecting its overall financial health beyond just this single metric.
How does Chemomab Therapeutics' Equity-to-Asset compare to TOVX and BIVI?
According to the Biotechnology industry distribution chart, Chemomab Therapeutics ranks #199 out of 1416 companies for Equity-to-Asset. This places Chemomab Therapeutics in the top 14% of its industry — outperforming the majority of peers. The industry median Equity-to-Asset is 0.68. Chemomab Therapeutics' value of 0.91 is 33.8% above this benchmark. Historically, Chemomab Therapeutics' own Equity-to-Asset has ranged from 0.69 to 0.97 over the past decade. While the company's 10-year median is 0.87 vs. the industry median of 0.68, Chemomab Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Biotechnology company?
The median Equity-to-Asset among Biotechnology companies is 0.68, based on 1,416 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Chemomab Therapeutics's current Equity-to-Asset of 0.91 is 33.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Chemomab Therapeutics and its competitors. For the Biotechnology industry, the median Equity-to-Asset is 0.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Chemomab Therapeutics's current Equity-to-Asset is 0.91, which is near median its own 10-year median of 0.87. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chemomab Therapeutics stock overvalued right now?
Chemomab Therapeutics (CMMB) has a current Equity-to-Asset of 0.91. The current Equity-to-Asset is 0.91, which is near median its 10-year median of 0.87 and 33.8% above the Biotechnology industry median of 0.68. Chemomab Therapeutics' overall GF Score™ is 36/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Chemomab Therapeutics (CMMB), the current Equity-to-Asset is 0.91 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Chemomab Therapeutics Ltd is a clinical-stage biotechnology company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases.
36GF Score
Get the complete analysis for CMMB
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CMMB has been successfully added to your 
